Clinical Use of Mifepristone (RU 486)

References

• Baulleu E E. Génération Pilule. Éditions Odile Jacob, Paris 1990
   Google Scholar
• Csapo Al, Pulkkinen M O. Indispensability of the human corpus luteum in the maintenance of early pregnancy. Obstet Gynecol Survey 1978; 33: 69–81
   PubMedGoogle Scholar
• Ulmann A, Teutsch G, Phlllbert D. RU 486. Sci Am 1990; 262: 18–24
   PubMed Web of Science ®Google Scholar
• Herman W, Wyss R, Riondel A, et al. Effet dun stéroide antiprogesterone chez la femme: interruption du cycle menstrual et de la grossesse au début. CR Acad Sci Paris 1982; 933–8
   Google Scholar
• Van Look P FA, Bygdeman M. Antiprogestational steroids: a new dimension in human fertility regulation. Oxf, Rev Reprod Biol 1989; II: 1–60
   Google Scholar
• Couzinet B, Strat N L., Ulmann A, Baulieu E E., Schaison G. Termination of early pregnancy by the progesterone antagonist RU 486 (mifepristone). N Engl J Med 1986; 315: 1565–70
   PubMed Web of Science ®Google Scholar
• Bygdeman M, Swahn M L. Progesterone receptor blockage. Effect on uterine contractility and early pregnancy. Contraception 1985; 32: 45–51
   PubMed Web of Science ®Google Scholar
• Cameron I T., Michle A F., Balrd D T. Therapeutic abortion in early pregnancy with antiprogestogen RU 486 alone or in combination with prostaglandin analogue (gemeprost). Contraception 1986; 34: 459–67
   PubMed Web of Science ®Google Scholar
• UK Multicentre Trial. The efficacy and tolerance of mifepristone and prostaglandin in first trimester of pregnancy. Br J Obstet Gynaecol 1990; 97: 480–6
   PubMedGoogle Scholar
• Silvestre L, Dubois C, Renault M, Rezvani Y, Baulie E E., Ulmann A. Voluntary interruption of pregnancy with mifepristone (RU 486) and a prostaglandin analogue. N Engl J Med 1990; 322: 645–8
   PubMed Web of Science ®Google Scholar
• Heikinheimo O, Lähteenmäki P LA, Koivunen E, et al. Metabolism and serum binding of RU 486 in women after various single doses. Hum Reprod 1987; 2: 379–86
   PubMed Web of Science ®Google Scholar
• Rodger M W., Balrd D T. Induction of therapeutic abortion in early pregnancy with mifepristone in combination with prostaglandin pessary. Lancet 1987; II: 1417–8
   Google Scholar
• Dubois C, Ulmann A, Aubeny E, et al. RU 486-A contragestive agent: association to a prostaglandin analogue. CR Acad Sci Ser III-VIE 1988; 306: 57–62
   PubMedGoogle Scholar
• Rodger M W., Baird D T. Blood loss following induction of early abortion using mifepristone (RU 486) and a prostaglandin analogue (gemeprost). Contraception 1989; 40: 439–47
   PubMed Web of Science ®Google Scholar
• Lim B H., Lees D AF, Bjornsson S, et al. Normal development after exposure to mifepristone in early pregnancy. Lancet 1990; 336: 257–8, (letter).
   PubMed Web of Science ®Google Scholar
• Pons J C., Elefant E, Herckorn P, Papiernik E. Development after exposure to mifepristone in early pregnancy. Lancet 1991; 338: 763
   PubMed Web of Science ®Google Scholar
• Baird D T., Rodger M W., Cameron I T., Roberts I. Prostaglandins and antigestogens for the interruption of early pregnancy. J Reprod Fertil Suppl 1988; 36: 173–9
   PubMedGoogle Scholar
• World Health Organization. Br Med J 1991; 303: 944
   Google Scholar
• World Health Organization. Pregnancy termination with mifepristone (RU 486) and gemeprost: a multicentre comparison between repeated doses and a single dose of mifepristone. Fertil Steril 1991; 56: 32–40
   PubMed Web of Science ®Google Scholar
• Anonymous. A death associated with mifepristone/sulprostone. Lancet 1991; 337: 969–70
   Web of Science ®Google Scholar
• Rodger M W., Logan A F., Baird D T. Induction of early abortion with mifepristone (RU 486) and two different doses of prostaglandin pessary (gemeprost). Contraception 1989; 39: 497–502
   PubMed Web of Science ®Google Scholar
• Norman J E., Thong K J., Baird D T. Increase in uterine contractility and induction of abortion in early pregnancy by misoprostol and mifepristone. Lancet 1991; 338: 1233–6
   PubMed Web of Science ®Google Scholar
• Aubeny E, Baulieu E E. Activité contragestide de I'association au RU 486 d'une prostaglandin active par voie orale. CR Acad Sci Paris 1991; 312: 539–46
   PubMed Web of Science ®Google Scholar
• Thong K J., Baird D T. Induction of abortion with mifepristone and misoprostol in early pregnancy. Br J Obstet Gynaecol 1992, (in press)
   Google Scholar
• Thong K J., Dewar M H., Baird D T. What do women want during medical abortion?. Contraception 1992; 45: 435–42
   Google Scholar
• Urquhart D R., Templeton A A. The use of mifepristone prior to prostaglandin-induced midtrimester abortion. Hum Reprod 1990; 5: 883–6
   PubMed Web of Science ®Google Scholar
• Rodger M W., Baird D T. Pretreatment with mifepristone (RU 486) reduces prostaglandin abortion interval in mid-trimester therapeutic abortion. Br J Obstet Gynaecol 1990; 97: 41–5
   PubMedGoogle Scholar
• Rådestad A, Christensen N J., Strömberg L. Induced cervical ripening with mifepristone in first trimester abortion: a double-blind randomized biomechanical study. Contraception 1988; 38: 301–12
   PubMed Web of Science ®Google Scholar
• Thong K J., Baird D T. A study of gemeprost alone, dilapan or mifepristone in combination with gemeprost for the termination of second trimester pregnancy. Contraception 1992; 46: 11–17
   PubMed Web of Science ®Google Scholar
• Baird D T. Medical termination of pregnancy. Recent advances in endocrinology and metabolism, C W. Edwards, D W. Lincoln. Churchill Livingstone, Edinburgh 1992; 14: 83–94
   Google Scholar